Tarsus Insider Sale: 6,000 Shares Sold Under 10b5-1 Plan
Rhea-AI Filing Summary
Tarsus Pharmaceuticals (TARS) reporting person Bobak R. Azamian, who serves as President/CEO and Board Chair, disclosed insider transactions on a Form 4. On 09/24/2025 the reporting person sold 6,000 shares of common stock in automatic transactions under a Rule 10b5-1 trading plan adopted December 12, 2024, at a weighted average price of $55.37 (sales ranged from $55.19 to $55.93). After the reported transactions the filing shows 812,106 shares beneficially owned indirectly (held in the Bobak Azamian Living Trust, of which he is trustee with voting and dispositive power) and 53,635 shares shown as disposed on a separate line. The Form 4 is signed by an attorney-in-fact on behalf of the reporting person.
Positive
- Transaction conducted under a Rule 10b5-1 plan, indicating preplanned sales and reducing concerns about opportunistic insider timing
- Clear disclosure of indirect ownership and trustee role for the Bobak Azamian Living Trust, including voting and dispositive power
- Weighted average sale price disclosed and seller offers to provide per-trade price details on request, supporting transparency
Negative
- None.
Insights
TL;DR: Routine, preplanned insider sale under a 10b5-1 plan; modest volume relative to reported holdings.
The Form 4 documents a sale of 6,000 shares executed pursuant to a Rule 10b5-1 plan adopted on December 12, 2024. The sale price is a weighted average of $55.37 with transactions between $55.19 and $55.93. These details indicate the trades were prearranged and not opportunistic market timing by the reporting person. The reporting person retains substantial indirect ownership (812,106 shares) through a living trust, and the filing discloses voting and dispositive power. From a market-impact perspective, the disclosed sale size appears small versus the reported indirect holdings.
TL;DR: Disclosure follows standard governance practice; trustee status and 10b5-1 plan are clearly stated.
The Form 4 provides governance-relevant details: the reporting person is President/CEO and Board Chair and is the trustee of a living trust holding the majority of disclosed indirect shares. The filing explicitly states the sale was effected under a Rule 10b5-1 plan, and the filer offers to supply detailed price-by-price information upon request, which supports transparency. The signature by an attorney-in-fact is noted and dated 09/26/2025, consistent with procedural execution of SEC filing requirements.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 6,000 | $55.37 | $332K |
| holding | Common Stock | -- | -- | -- |
Footnotes (1)
- The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 12, 2024. The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $55.19 to $55.93. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The Reporting Person is the trustee of the Bobak Azamian Living Trust, established April 16, 2018 and has voting and dispositive power with respect to these shares.
